Malignant hyperthermia when dantrolene is not readily available

• Published in: BMC anesthesiology Vol. 21; no. 1; pp. 119 - 11
• Main Author: Gong, Xiaodan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.04.2021; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Analysis; Anesthesia; Anesthetics; Arterial Pressure; Blood Coagulation Disorders - epidemiology; Blood pressure; Carbon dioxide; Carbon Dioxide - metabolism; Child; Child, Preschool; China - epidemiology; Congenital diseases; Creatine; Creatine kinase; Creatine Kinase - blood; Creatine Kinase, MB Form - blood; Dantrolene; Dantrolene - supply & distribution; Databases, Factual; Death; Enzyme; Enzymes; Female; Fever; Furosemide; Humans; Hydrogen-Ion Concentration; Hyperthermia; Infant; Infant, Newborn; Ketamine; Laboratories; Male; Malignant hyperthermia; Malignant Hyperthermia - epidemiology; Mannitol; Middle Aged; Mortality; Muscle Relaxants, Central - supply & distribution; Myoglobin; Myoglobin - blood; Myoglobins; Patients; Potassium - blood; Signs; Succinylcholine; Tidal Volume; Treatment; Young Adult; China; Treatment; Dantrolene; Malignant hyperthermia; Enzyme; Mortality

Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both. Unfortunately, the specific medicine dantrolene is not readi...